ALAYA.BIO Trademark

Trademark Overview


On Friday, July 26, 2024, a trademark application was filed for ALAYA.BIO with the United States Patent and Trademark Office. The USPTO has given the ALAYA.BIO trademark a serial number of 79408189. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, September 30, 2025. This trademark is owned by Alaya.bio. The ALAYA.BIO trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Biotechnology-derived products and preparations applied to the medical field, namely, gene and cell therapy products and preparations for medical purposes; gene and cell therapy products and preparations, namely, cells targeting polymeric nanoparticle based on vector payloads for medical purposes; medical products, substances and preparations, namely, biotechnology-derived products and preparations being cell targeting preparations and products in the nature of polymeric nanoparticle based on vector payloads and pharmaceutical products for immunotherapy and cancer treatment, autoimmune diseases, genetic diseases, diseases affecting the central nervous system; none of the aforementioned goods relating to or being in the nature of nutritional supplements

Medical research; pharmacological research being pharmaceutical research services; research and development in the field of biotechnology; biotechnology advice, namely, consulting services in the field of biotechnology and cell and gene therapy; preparation of reports in the field of biotechnology for scientific research purposes; information about scientific research in the field of biochemistry and biotechnology; scientific research in the fields of cell therapy and gene therapy; scientific research in the fields of in-vivo gene therapy and cell therapy; medical and scientific research in the field of immunotherapy; medical and scientific research in the field of oncology; medical and scientific research in the field of autoimmune disease; medical and scientific research in the field of genetic disease; medical and scientific research in the field of diseases affecting the central nervous system
alaya.bio

General Information


Serial Number79408189
Word MarkALAYA.BIO
Filing DateFriday, July 26, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateTuesday, September 30, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesBiotechnology-derived products and preparations applied to the medical field, namely, gene and cell therapy products and preparations for medical purposes; gene and cell therapy products and preparations, namely, cells targeting polymeric nanoparticle based on vector payloads for medical purposes; medical products, substances and preparations, namely, biotechnology-derived products and preparations being cell targeting preparations and products in the nature of polymeric nanoparticle based on vector payloads and pharmaceutical products for immunotherapy and cancer treatment, autoimmune diseases, genetic diseases, diseases affecting the central nervous system; none of the aforementioned goods relating to or being in the nature of nutritional supplements
Pseudo MarkALAYA BIO
Goods and ServicesMedical research; pharmacological research being pharmaceutical research services; research and development in the field of biotechnology; biotechnology advice, namely, consulting services in the field of biotechnology and cell and gene therapy; preparation of reports in the field of biotechnology for scientific research purposes; information about scientific research in the field of biochemistry and biotechnology; scientific research in the fields of cell therapy and gene therapy; scientific research in the fields of in-vivo gene therapy and cell therapy; medical and scientific research in the field of immunotherapy; medical and scientific research in the field of oncology; medical and scientific research in the field of autoimmune disease; medical and scientific research in the field of genetic disease; medical and scientific research in the field of diseases affecting the central nervous system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 31, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, October 31, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAlaya.bio
Party Type10 - Original Applicant
Legal Entity Type34 - NOT AVAILABLE
AddressFR

Trademark Events


Event DateEvent Description
Thursday, October 31, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, November 1, 2024APPLICATION FILING RECEIPT MAILED
Friday, November 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 3, 2025ASSIGNED TO EXAMINER
Tuesday, February 25, 2025NON-FINAL ACTION WRITTEN
Monday, March 31, 2025REFUSAL PROCESSED BY MPU
Wednesday, February 26, 2025NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, March 31, 2025NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, April 19, 2025REFUSAL PROCESSED BY IB
Tuesday, September 30, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 30, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 30, 2025TEAS/EMAIL CORRESPONDENCE ENTERED